Back to Search
Start Over
Prognostic power of soluble urokinase plasminogen activator receptor (suPAR) for short-term mortality in patients seen in Emergency Departments due to infections
- Source :
- Revista Española de Quimioterapia. 35:50-62
- Publication Year :
- 2021
- Publisher :
- Sociedad Espanola de Quimioterapia, 2021.
-
Abstract
- Objectives. To analyse and compare 30-day mortality prognostic power of several biomarkers (C-reactive protein, procalcitonin, lactate and suPAR) in patients seen in emergency departments (ED) due to infections. Secondly, if these could improve the accuracy of systemic inflammatory response syndrome (SIRS) and quick Sepsis-related Organ Failure Assessment (qSOFA). Methods. A prospective, observational and analytical study was carried out on patients who were treated in an ED of one of the eight participating hospitals. An assessment was made of 32 independent variables that could influence mortality at 30 days. They covered epidemiological, comorbidity, functional, clinical and analytical factors. Results. The study included 347 consecutive patients, 54 (15.6%) of whom died within 30 days of visiting the ED. SUPAR has got the best biomarker area under the curve (AUC)-ROC to predict mortality at 30 days of 0.836 (95% CI: 0.765-0.907; P 10 ng/mL who had a sensitivity of 70% and a specificity of 86%. The score qSOFA ≥ 2 had AUC-ROC of 0.707 (95% CI: 0.621-0.793; P < .001) with sensitivity of 53% and a specificity of 89%. The mixed model (suPAR > 10 ng/mL plus qSOFA ≥ 2) has improved the AUC-ROC to 0.853 [95% CI: 0.790-0.916; P < .001] with the best prognostic performance: sensitivity of 39% and a specificity of 97% with a negative predictive value of 90%. Conclusions. suPAR showed better performance for 30-day mortality prognostic power from several biomarkers in the patients seen in ED due to infections. Score qSOFA has better performance that SRIS and the mixed model (qSOFA ≥ 2 plus suPAR > 10 ng/mL) increased the ability of qSOFA.
- Subjects :
- Microbiology (medical)
Pharmacology
medicine.medical_specialty
biology
business.industry
C-reactive protein
Area under the curve
General Medicine
Emergency department
medicine.disease
Comorbidity
Procalcitonin
Systemic inflammatory response syndrome
SuPAR
Internal medicine
Epidemiology
medicine
biology.protein
business
Subjects
Details
- ISSN :
- 19889518 and 02143429
- Volume :
- 35
- Database :
- OpenAIRE
- Journal :
- Revista Española de Quimioterapia
- Accession number :
- edsair.doi...........e8a4740073820ef9174ccb96ed8c6fed
- Full Text :
- https://doi.org/10.37201/req/108.2021